<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203160</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2019.116</org_study_id>
    <secondary_id>HUM00170490</secondary_id>
    <nct_id>NCT04203160</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)</brief_title>
  <official_title>A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety and efficacy of CPI-613&#xD;
      (devimistat) in the treatment of advanced biliary tract cancer when used in combination with&#xD;
      standard of care chemotherapy (gemcitabine plus cisplatin) compared to gemcitabine plus&#xD;
      cisplatin alone.&#xD;
&#xD;
      This research study has two parts:&#xD;
&#xD;
      In the phase 1 portion of this study, patients will receive a combination of CPI-613 and&#xD;
      standard of care chemotherapy. Dose levels of CPI-613 will be adjusted to find the best dose,&#xD;
      which will be the recommended phase 2 dose level.&#xD;
&#xD;
      In the phase 2 portion of this study, patients will be randomized into two arms. Patients in&#xD;
      Arm A will receive the combination of the recommended dose level of CPI-613 and standard of&#xD;
      care chemotherapy. Patients in Arm B will receive standard of care chemotherapy.&#xD;
&#xD;
      At the end of the study, researchers will compare the health outcomes of the patients that&#xD;
      received CPI-613 + standard care to the outcomes of patients that received only standard&#xD;
      care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase II: 2:1 Randomization with Bayesian Design Control Arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Incidence of dose-limiting toxicity</measure>
    <time_frame>Up to day 22</time_frame>
    <description>Dose limiting toxicities will determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of combination therapy with CPI-613 + gemcitabine and cisplatin. Assessed using the NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Overall Response Rate (ORR)</measure>
    <time_frame>Until last dose of study treatment (up to 2 years)</time_frame>
    <description>Objective response assessment will be determined by review of CT or MR scans of the chest, abdomen and pelvis. ORR (Partial Response + Complete Response) will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, during active study treatment. All enrolled patients who receive at least 1 cycle of therapy and have their disease re-evaluated will be considered evaluable for response. (Note: Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Progression Free Survival (PFS)</measure>
    <time_frame>Until last dose of study treatment (up to 2 years)</time_frame>
    <description>PFS will be determined from date of first study treatment until the date of radiological or clinical progression (leading to withdrawal from the study) or date of last disease evaluation (for patients without progression). It will be calculated using the product-limit method of Kaplan and Meier. All patients that receive at least one dose of study treatment will be considered evaluable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (OS)</measure>
    <time_frame>Up to 3 years after enrollment</time_frame>
    <description>From date of first study treatment until date of last disease evaluation or until death from any cause. Using the product-limit method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Toxicities</measure>
    <time_frame>Up to 100 days after last dose of study treatment</time_frame>
    <description>To evaluate the safety of CPI-613 in combination with gemcitabine and cisplatin in this patient population, assessed using the Common Toxicity Criteria for Adverse Events (CTCAE) v5.0. All patients that receive at least one dose of study treatment will be considered evaluable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 1 and Phase 2, Arm A (investigational)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On Day 1 and Day 8 of each 3-week cycle, patients will receive CPI-613 + gemcitabine and cisplatin. Patients may continue gemcitabine, cisplatin and CPI-613 for up to 2 years in absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2, Arm B (standard of care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1 and Day 8 of each 3-week cycle, patients will receive gemcitabine and cisplatin. Patients may continue gemcitabine and cisplatin for up to 2 years in absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI 613</intervention_name>
    <description>Given intravenously</description>
    <arm_group_label>Phase 1 and Phase 2, Arm A (investigational)</arm_group_label>
    <other_name>Devimistat®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Given intravenously</description>
    <arm_group_label>Phase 1 and Phase 2, Arm A (investigational)</arm_group_label>
    <arm_group_label>Phase 2, Arm B (standard of care)</arm_group_label>
    <other_name>Gemzar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given intravenously</description>
    <arm_group_label>Phase 1 and Phase 2, Arm A (investigational)</arm_group_label>
    <arm_group_label>Phase 2, Arm B (standard of care)</arm_group_label>
    <other_name>CDDP, Platinol®, NSC-119875</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Patients must have a pathologically or cytologically confirmed carcinoma (except&#xD;
             neuroendocrine) of the biliary tract (intra-hepatic, extra-hepatic (hilar, distal) or&#xD;
             gallbladder) that is not eligible for curative resection, transplantation, or ablative&#xD;
             therapies. Tumors of mixed cholangiocarcinoma/hepatocellular carcinoma histology are&#xD;
             excluded.&#xD;
&#xD;
          -  Patients may not have received prior systemic treatment (chemotherapy or targeted&#xD;
             therapy) for advanced BTC. Prior peri-operative chemotherapy is permitted provided it&#xD;
             was completed &gt; 6 months from enrollment.&#xD;
&#xD;
          -  Patients may have received prior radiation, chemoembolization, radioembolization or&#xD;
             other local ablative therapies or hepatic resection if completed ≥ 4 weeks prior to&#xD;
             enrollment AND if patient has recovered to ≤ grade 1 toxicity. Extrahepatic palliative&#xD;
             radiation is permitted if completed ≥ 2 weeks prior to enrollment AND if patient has&#xD;
             recovered to ≤ grade 1 toxicity&#xD;
&#xD;
          -  Patients must have radiographically measurable disease (as per RECISTv1.1) in at least&#xD;
             one site not previously treated with radiation or liver directed therapy (including&#xD;
             bland, chemo- or radio-embolization, or ablation) either within the liver or in a&#xD;
             metastatic site.&#xD;
&#xD;
          -  Must be ≥ 18 years of age.&#xD;
&#xD;
          -  Must have an ECOG performance status of 0-1.&#xD;
&#xD;
          -  Ability to understand and willingness to sign IRB-approved informed consent.&#xD;
&#xD;
          -  Willing to provide archived tissue, if available, from a previous diagnostic biopsy.&#xD;
&#xD;
          -  Must be able to tolerate CT and/or MRI with contrast.&#xD;
&#xD;
          -  Adequate organ function (per protocol) obtained ≤ 2 weeks prior to enrollment.&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use 2 methods of adequate&#xD;
             contraception (hormonal plus barrier or 2 barrier forms) OR abstinence prior to study&#xD;
             entry, for the duration of study participation and for 6 months (for men and women)&#xD;
             following completion of study therapy.&#xD;
&#xD;
        Exclusions:&#xD;
&#xD;
          -  Prior history of brain metastasis (unless previously treated, asymptomatic and stable&#xD;
             for at least 3 months) or organ transplant.&#xD;
&#xD;
          -  Underwent a major surgical procedure &lt; 4 weeks prior to enrollment.&#xD;
&#xD;
          -  Active second malignancy other than in situ cancer or localized prostate cancer&#xD;
             (Gleason score &lt;8). Patients with history of other malignancy are eligible provided&#xD;
             primary treatment of that cancer was completed &gt; 1 year prior to enrollment and the&#xD;
             patient is free of clinical or radiologic evidence of recurrent or progressive&#xD;
             malignancy.&#xD;
&#xD;
          -  Ongoing active, uncontrolled infection (must be afebrile for &gt; 48 hours off&#xD;
             antibiotics) .&#xD;
&#xD;
          -  Psychiatric illness, other significant medical illness, or social situation which, in&#xD;
             the investigator's opinion, would limit compliance or ability to comply with study&#xD;
             requirements.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. (Women must not be pregnant or breastfeeding since study&#xD;
             drugs may harm the fetus or child. All females of childbearing potential [not&#xD;
             surgically sterilized and between menarche and 1 year post menopause] must have a&#xD;
             negative screening pregnancy test.)&#xD;
&#xD;
          -  Active heart disease including symptomatic heart failure (NYHA class 3 or 4), unstable&#xD;
             angina pectoris, uncontrolled cardiac arrhythmia or interstitial lung disease.&#xD;
&#xD;
          -  Prisoners or subjects who are involuntarily incarcerated, or compulsorily detained for&#xD;
             treatment of either a psychiatric or physical (e.g. infectious disease) illness would&#xD;
             be excluded.&#xD;
&#xD;
          -  Prolonged QTcF interval &gt;480 msec.&#xD;
&#xD;
          -  Known hypersensitivity to cisplatin, gemcitabine or CPI-613, or its inactive&#xD;
             components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaibhav Sahai, MBBS, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachna Shroff, M.D.</last_name>
      <phone>520-626-4175</phone>
      <email>rshroff@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Rachna Shroff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University -- Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lurie Cancer Center</last_name>
      <phone>312-695-1102</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Devalingam Mahalingam, MBBChBAO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer AnswerLine</last_name>
      <phone>800-865-1125</phone>
      <email>CancerAnswerLine@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Vaibhav Sahai, MBBS, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Atlantic Hematology Oncology</last_name>
      <phone>973-971-7960</phone>
    </contact>
    <investigator>
      <last_name>Angela Alistar, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals - Seidman Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>UH Seidman CC</last_name>
      <phone>440-508-8663</phone>
    </contact>
    <investigator>
      <last_name>Richard Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Goff, M.D.</last_name>
      <phone>877-936-8422</phone>
      <email>laura.goff@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Laura Goff, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern -- Simmons Comprehensive Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Beg, M.D.</last_name>
      <phone>214-645-8300</phone>
      <email>Muhammad.Beg@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammad Beg, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zhen, M.D.</last_name>
      <phone>206-606-1743</phone>
      <email>dbzhen@uw.edu</email>
    </contact>
    <investigator>
      <last_name>David Zhen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin - Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dustin Deming, M.D.</last_name>
      <phone>608-265-1042</phone>
      <email>ddeming@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Dustin Deming, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Gallbladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

